Roivant Sciences Ltd. (ROIV) | Stock price, performance, AI analysis | Thematic | AI powered fundamental research and development platform

Loading...

Research a topic Stock screener Find companies

Search for securities Load an existing portfolio Backtest

Thematic overview Develop asset-backed products Company evaluations Backtesting and benchmarking Thematic branded indices

Research a topic Stock screener Find companies

Search for securities Load an existing portfolio Backtest

Thematic overview Develop asset-backed products Company evaluations Backtesting and benchmarking Thematic branded indices

Follow our journey and product updates

Product

Overview Company evaluations Research a topic

Company

About us Blog Contact

Legal

Terms Privacy Policy

Roivant Sciences Ltd. (ROIV)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about Roivant Sciences Ltd. (ROIV)

Company Performance

Current Price

as of Dec 03, 2024

$12.12

P/E Ratio

2.14

Market Cap

$8.82B

Description

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Metrics

Overview

HQLondon, GL
SectorHealth Technology
IndustryPharmaceuticals: Major
TickerROIV
Price$12.12-2.88%

Trading Information

Market cap$8.82B
Float51.83%
Average Daily Volume (1m)5,300,402
Average Daily Volume (3m)6,297,957
EPS$5.99

Company

Revenue$125.68M
Rev growth (1yr)-87.94%
Net income-$187.10M
Gross margin94.77%
EBITDA margin-7,656.58%
EBITDA-$342.63M

EV$3.58B
EV/Revenue28.46
P/E2.14
P/S70.93
P/B1.72

Documents

SEC Filings

8-K (2024-12-03)

8-K (2024-11-12)

8-K (2024-10-28)

8-K (2024-09-23)

8-K (2024-09-18)

8-K (2024-09-16)

8-K (2024-09-10)

8-K (2024-09-09)

8-K (2024-08-08)

8-K (2024-05-30)

8-K (2024-04-02)

8-K (2024-02-13)

8-K (2023-12-20)

8-K (2023-12-14)

8-K (2023-11-28)

8-K (2023-11-27)

8-K (2023-11-13)

8-K (2023-10-23)

8-K (2023-09-29)

8-K (2023-09-26)

8-K (2023-09-15)

8-K (2023-09-11)

8-K (2023-08-17)

8-K (2023-08-14)

8-K (2023-08-04)

8-K (2023-08-02)

8-K (2023-06-28)

8-K (2023-06-22)

8-K (2023-05-16)

8-K (2023-04-04)

8-K (2023-03-16)

8-K (2023-03-15)

8-K (2023-02-21)

8-K (2023-02-13)

8-K (2023-02-07)

8-K (2023-02-01)

8-K (2023-01-04)

10-Q (2024-11-12)

10-Q (2024-08-09)

10-Q (2024-02-13)

10-Q (2023-11-13)

10-Q (2023-08-14)

10-Q (2023-02-13)

10-K (2024-05-30)

10-K (2023-06-28)

Earnings Calls

Earnings Report 2025Q1

Earnings Report 2023Q4

Earnings Report 2023Q3

Earnings Report (2023-11-13)

Earnings Report (2023-08-14)

Factset

Factset Business Description

Factset Street Account

StreetAccount Earnings Call Q&A Summary: Roivant Sciences Q2 ($8.81, 0.00) (2023-11-13T14:33:27Z)

Roivant Sciences reports Q2 EPS ($0.29) ex-items vs FactSet ($0.29) [10 est, ($0.34)-(0.17)] ($8.81, 0.00) (2023-11-13T12:06:37Z)

Roivant Sciences initiated buy at Guggenheim Securities ($10.19, 0.00) (2023-10-17T10:18:47Z)

Roivant and Priovant announce results from phase 2 study of oral Brepocitinib in systemic lupus Erythematosus ($9.13, 0.00) (2023-11-27T13:02:50Z)

Follow-up: Roche to acquire Telavant for $7.1B (CHF6.35B) up front ($9.66, 0.00) (2023-10-23T05:46:10Z)

Wikipedia

Roivant_Sciences